Nature Medicine has published an author correction to the phase 1 trial evaluating ABBV-706, a SEZ6-targeting antibody-drug conjugate (ADC) designed for advanced small cell lung cancer and solid tumors. The correction, published online on 29 June 2026, addresses methodological clarifications and factual updates to the original trial report.
Author corrections serve as a critical quality-assurance mechanism in peer-reviewed publishing, ensuring that clinical trial data remains accurate and transparent. Rather than indicating research misconduct, such corrections typically reflect minor adjustments—clerical corrections, data clarifications, or methodological refinements—that strengthen the integrity of the published record.
This update underscores the rigorous post-publication oversight systems that maintain confidence in oncology trial evidence. ABBV-706 continues advancing through development as a next-generation precision medicine for patients with treatment-resistant malignancies.
Read the full article on GMJ Newsroom.
Was this article helpful?
